NCT03781219 2023-05-31A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 MutationShanghai Kechow Pharma, Inc.Phase 1 Unknown45 enrolled
NCT01596140 2020-06-04Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced CancerM.D. Anderson Cancer CenterPhase 1 Completed27 enrolled
NCT02638428 2020-03-19Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancySamsung Medical CenterPhase 2 Unknown90 enrolled